Literature DB >> 10870534

Clinical pathway for fractured neck of femur: a prospective, controlled study.

P F Choong1, A K Langford, M M Dowsey, N M Santamaria.   

Abstract

OBJECTIVE: To assess outcomes of using a clinical pathway for managing patients with fractured neck of femur.
DESIGN: Prospective, pseudorandomised, controlled trial.
SETTING: St Vincent's Hospital, Melbourne, Victoria (a tertiary referral, university teaching hospital), 1 October 1997 to 30 November 1998. PARTICIPANTS: 111 patients (80 women and 31 men; mean age, 81 years) admitted via the emergency department with a primary diagnosis of fractured neck of femur.
INTERVENTIONS: Management guided by a clinical pathway (55 patients) or established standard of care (control group, 56 patients). MAIN OUTCOME MEASURES: Timing of referrals and discharge planning; total length of stay; and complication and readmission rates within 28 days of discharge.
RESULTS: Patients managed according to the clinical pathway had a shorter total stay (6.6 versus 8.0 days; P = 0.03), even if assessment for placement by the Aged Care Assessment Service was required (9.5 versus 13.6 days; P = 0.03). There were no significant differences in complication and readmission rates between pathway and control patients (complication rates, 24% versus 36%; P = 0.40; readmission rates, 4% versus 11%; P = 0.28).
CONCLUSION: Coordinated multidisciplinary care of patients with fractured neck of femur reduces length of stay without increasing complications.

Entities:  

Mesh:

Year:  2000        PMID: 10870534     DOI: 10.5694/j.1326-5377.2000.tb124038.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  30 in total

Review 1.  Best practices for elderly hip fracture patients. A systematic overview of the evidence.

Authors:  Lauren A Beaupre; C Allyson Jones; L Duncan Saunders; D William C Johnston; Jeanette Buckingham; Sumit R Majumdar
Journal:  J Gen Intern Med       Date:  2005-11       Impact factor: 5.128

2.  Intermediate care--Hospital-at-Home in chronic obstructive pulmonary disease: British Thoracic Society guideline.

Authors: 
Journal:  Thorax       Date:  2006-11-07       Impact factor: 9.139

3.  Early prediction of gait ability in patients with hip fracture.

Authors:  Eiki Tsushima; Ryukichi Hada; Manabu Iwata; Hitoshi Tsushima
Journal:  Environ Health Prev Med       Date:  2009-03-27       Impact factor: 3.674

4.  [IT-based clinical pathway as a routine tool in trauma surgery].

Authors:  L Homagk; O Deml; G O Hofmann
Journal:  Unfallchirurg       Date:  2012-12       Impact factor: 1.000

5.  The effectiveness of a multidisciplinary hip fracture care model in improving the clinical outcome and the average cost of manpower.

Authors:  T W Lau; C Fang; F Leung
Journal:  Osteoporos Int       Date:  2016-11-26       Impact factor: 4.507

Review 6.  The effect of care pathways for hip fractures: a systematic overview of secondary studies.

Authors:  Fabrizio Leigheb; Kris Vanhaecht; Walter Sermeus; Cathy Lodewijckx; Svin Deneckere; Steven Boonen; Paulo A Boto; Rita Veloso Mendes; Massimiliano Panella
Journal:  Eur J Orthop Surg Traumatol       Date:  2012-09-25

7.  Reduced morbidity for elderly patients with a hip fracture after implementation of a perioperative evidence-based clinical pathway.

Authors:  L A Beaupre; J G Cinats; A Senthilselvan; D Lier; C A Jones; A Scharfenberger; D W C Johnston; L D Saunders
Journal:  Qual Saf Health Care       Date:  2006-10

Review 8.  Perioperative fluid volume optimization following proximal femoral fracture.

Authors:  Sharon R Lewis; Andrew R Butler; Andrew Brammar; Amanda Nicholson; Andrew F Smith
Journal:  Cochrane Database Syst Rev       Date:  2016-03-14

9.  [Clinical pathways: effective and efficient inpatient treatment].

Authors:  N Roeder; P Hensen; D Hindle; N Loskamp; H-J Lakomek
Journal:  Chirurg       Date:  2003-12       Impact factor: 0.955

Review 10.  Post-operative considerations in hip fracture management.

Authors:  Michael H Freitag; Jay Magaziner
Journal:  Curr Rheumatol Rep       Date:  2006-02       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.